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Abstract
Background Most surgical prophylaxis guidelines recommend a 3-g cefazolin intravenous dose in patients weighing ≥ 120 kg.
However, this recommendation is primarily based on pharmacokinetic studies rather than robust clinical evidence. This study
aimed to compare the prevalence of surgical site infections (SSIs) in obese and non-obese patients (body mass index ≥ 30 kg/m2
and < 30 kg/m2), and those weighing ≥ 120 kg and < 120 kg, who received 2- g cefazolin preoperatively.
Methods A retrospective case-control study was conducted in adult elective surgical patients. Patients receiving 2- g cefazolin
were grouped as obese and non-obese, and by weight (≥ 120 kg or < 120 kg). The 90-day prevalence of SSI and potential
contributing factors were investigated.
Results We identified 152 obese (median 134 kg) and 152 non-obese control (median 73 kg) patients. Baseline characteristics
were similar between groups, except for an increased prevalence in the obese group of diabetes (35.5% vs 13.2%; p < 0.001) and
an American Society of Anaesthesiologists Score of 3 (61.8% vs 17.1%; p < 0.001). While not statistically significant, the
prevalence of SSI in the obese group was almost double that in the non-obese group (8.6% vs 4.6%; p = 0.25) and in patients
weighing ≥ 120 kg (n = 102) compared to those weighing < 120 kg (n = 202) (9.8% vs 5.0%; p = 0.17).
Conclusion The prevalence of SSI was not significantly increased in obese patients, or those weighing ≥ 120 kg, who received
cefazolin 2- g prophylactically; however, trends toward an increase were evident. Large-scale randomised trials are needed to
examine whether a 2-g or 3-g cefazolin is adequate to prevent SSI in obese (and ≥ 120 kg) individuals.
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Introduction
Obese patients undergo surgical procedures more frequently
than their non-obese counterparts due to obesity-related health
problems, such as osteoarthritis, cardiovascular disease, dia-
betes and cancer [1]. Obesity is also associated with a number
of surgical complications, including an increased risk of sur-
gical site infection (SSI) [2]. The repercussions of SSI include
extended hospital stay, more frequent hospital readmissions,
pain, anxiety and higher healthcare resource utilisation [3].
However, the administration of an appropriate antibiotic at
an appropriate dose before surgery significantly reduces the
risk of SSI [4].
Cefazolin remains the drug of choice for surgical prophy-
laxis in many procedures due to its favourable safety profile,
low cost and targeted activity against the microorganisms
commonly encountered during surgical procedures [4]. In
2013, a collective guideline for surgical prophylaxis devel-
oped by the Infectious Diseases Society of America (IDSA),
American Society of Health-System Pharmacists (ASHP),
Surgical Infection Society (SIS) and Society for Healthcare
Epidemiology of America (SHEA), suggested an increased
dose of cefazolin (3- g intravenously) for patients weighing
≥ 120 kg [4]. Similarly, the Australian Medicines Handbook
(AMH) recommends a 3-g dose of cefazolin for patients >
120 kg [5]. The American Journal of Obstetricians and
Gynaecologists (ACOG) Practice Bulletin and the Australian
* Syed Tabish R. Zaidi
S.T.R.Zaidi@leeds.ac.uk
1 Division of Pharmacy, College of Health andMedicine, University of
Tasmania, Hobart, Tasmania, Australia
2 Department of Anaesthesia, Launceston General Hospital,
Launceston, Tasmania, Australia
3 Head of Anaesthesia Discipline, Launceston Clinical School,
University of Tasmania, Launceston, Tasmania, Australia
4 School of Healthcare, University of Leeds, Leeds LS2 9JT, UK
Obesity Surgery (2019) 29:159–165
https://doi.org/10.1007/s11695-018-3497-0
The Author(s) 2018
Therapeutic Guidelines (TG) also suggest the need for a
higher prophylactic cefazolin dose for obese surgical patients
but do not specify the recommended dose or weight or BMI
cut-off values [6, 7].
The dosing recommendations of those guidelines were
based on small-scale and inconsistent pharmacokinetic studies
(level-III according to the National Health and Medical
Research Council levels of evidence) [8]. Four pharmacoki-
netic studies found that a 2-g prophylactic dose of cefazolin
may be inadequate in morbidly obese patients undergoing
bariatric procedures and caesarean section, due to the blood
and/or tissue drug concentrations being below minimum in-
hibitory concentrations (MIC) [9–12]. These studies sug-
gested the need for a higher (3- g) dose in these patients. In
contrast, six pharmacokinetic studies in similar surgical spe-
cialties found that a 2-g dose did provide adequate antimicro-
bial coverage (concentration above MIC) in morbidly obese
patients with similar weight ranges, suggesting no dose incre-
ment was required [13–18].
Given the lack of satisfactory evidence supporting 3- g
dosing in obese patients and a scarcity of clinical outcome
studies, this study sought to ascertain whether an intravenous
2- g dose of cefazolin was comparatively effective in obese
versus non-obese surgical patients, and in those who weighed
above or below 120 kg, based on the observed rate of SSI
within 90 days of operation.
Method
A retrospective 1:1 case-control study was conducted of obese
(BMI ≥ 30 kg/m2) and non-obese adults who underwent elec-
tive surgical procedures at the Royal Hobart Hospital (RHH)
from 1 Jan 2012 to 31 Dec 2016. The prevalence of SSI at this
institution was not known, so a duration-based (5-year) sam-
pling method was used. The 500-bed RHH is the largest pub-
lic teaching and referral hospital in the state of Tasmania,
Australia. Ethical approval was obtained from the
Tasmanian Health and Human Research Ethics Committee
(H0015795). Informed consent from patients was not needed
as data was collected retrospectively and de-identified upon
collection.
Patients were included if they were at least 18 years of age
and had received prophylactic cefazolin pre-operatively. The
reasons for selecting elective cases were that more detailed
documentation was available for these patients; they were
more likely to have adequate pre-operative optimisation of
medical comorbidities and a lower incidence of pre-
operative bacterial colonisation compared to emergency cases
[19, 20]. Patients were excluded if they (i) lacked follow-up
within 90 days of surgery, (ii) had an unplanned non-infective
post-operative intensive care unit admission, (iii) had a second
operation during the same admission for causes other than
infection, (iv) required perioperative blood transfusion, (v)
were taking systemic immunosuppressive medication (corti-
costeroids, sirolimus, everolimus, cyclosporine, tacrolimus,
azathioprine, mycophenolate, monoclonal antibodies or bio-
logics, e.g. abatacept, etanercept) at admission and/or dis-
charge, (vi) were receiving antibiotics immediately prior to
admission or (vii) had missing requisite data (such as antibi-
otic type, dose, or surgical duration) in their medical record.
Aside from BMI, the same inclusion and exclusion criteria
were applied to obtain the non-obese (BMI < 30 kg/m2) con-
trol patients.
A list of obese patients, based on the International
Classification of Disease-10 (ICD-10), who underwent elec-
tive surgical procedures during 2012 to 2016, was obtained
from the hospital’s coding database. The list was then
reviewed to identify patients who met the inclusion criteria.
To include non-obese control patients, a list of similar elective
surgical procedures from 2012 to 2016 was systematically
screened, by including every fifth patient if they met the study
inclusion criteria, until we reached approximately equal num-
bers in every surgical speciality to that of obese group.
Patients’ medical records were reviewed to obtain socio-
demographic and clinical information, including gender, age,
weight, height, body mass index (BMI), smoking status, dia-
betes status, length of stay (LOS), American Society of
Anaesthesiologists (ASA) score [21], surgical wound class,
duration of surgery, post-operative antibiotic use, surgical spe-
cialty and SSI incidence. Diabetes was identified based on a
recorded diagnosis or use of any medication for diabetes man-
agement at admission or discharge. Wound class was
categorised based on the Centre for Disease Control and
Prevention Centre (CDC) criteria [22]. Duration of surgery
was calculated as the time between skin incision and skin
closure. LOS was calculated from date of admission until
date of discharge in patients who did not develop SSI dur-
ing admission or until date of SSI development for those
who developed SSI during admission. Surgical procedures
were grouped into a surgical specialty based on the depart-
ment in which the patient underwent surgery, i.e. general
surgery (such as laparoscopic adjustable gastric banding,
laparoscopic cholecystectomy, incisional hernia repair),
gynaecological surgery (such as caesarean section, hyster-
ectomy, ovarian cystectomy) and orthopaedic surgery
(such as hip and knee replacement, hip arthroplasty, ankle
fracture). Prophylactic pre-operative cefazolin dose and
post-operative antibiotic use (when not for SSI treatment)
were recorded. Inpatient, outpatient and emergency depart-
ment notes were screened for up to 90 days post-
operatively to identify documented SSIs, which were clas-
sified into superficial, deep and organ/space, in accordance
with the CDC [22].
Continuous variables were expressed as median (interquar-
tile range) and categorical variables as the count (percentage).
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Pearson’s χ2 test and Fisher’s exact test were used for cate-
gorical variables, and the Mann-Whitney U test was used for
continuous variables to compare the baseline variables and
primary outcome. Logistic regression was used to identify
the potential predictors of SSI. Variables (other than ASA
score, post-operative antibiotic use and wound class) from
the univariate analysis with a p value ≤ 0.20 were included
in the multivariate logistic regression model. ASA score was
not included in the multivariate analysis because it depends
on two other study variables, diabetes and body weight.
Post-operative antibiotic use was also not included in the
multivariate analysis because its use was limited to certain
surgical specialties, such as orthopaedics, and given to on-
ly 14% of patients. Wound class was also not included in
the multivariate analysis because of the very small number
of patients with contaminated and dirty wounds. The re-
gression analysis was presented as unadjusted and adjusted
odds ratios (OR) and 95% confidence intervals (CI). A p
value of < 0.05 was considered significant in all the statis-
tical analyses. Analyses were performed using SPSS ver-
sion 22 (IBM Inc., Chicago, IL).
Results
One hundred and fifty-two obese patients met the inclusion
criteria for this study andwerematchedwith non-obese controls
(Fig. 1). Patient characteristics are described in Table 1. There
were differences between the obese and non-obese groups in
median body weight (133.5 kg vs 72.5 kg, p < 0.001), median
BMI (47.0 kg/m2 vs 26.7 kg/m2, p < 0.001), presence of diabe-
tes (35.5% vs 13.2%, p < 0.001) and ASA score (score 3 in
61.8% vs 17.1%, p < 0.001). Overall, nearly two thirds
(64.5%) were general surgical patients and more than half
had a clean surgical wound in each group (non-obese =
58.6% and obese = 61.8%). Less than 2% of patients in
either group were given prophylactic antibiotics when it
was not recommended according to the Australian TG [7].
Thirteen (8.6%) obese and 7 (4.6%) non-obese patients de-
veloped SSIs (p = 0.25; Table 2). Similarly, the observed rate of
SSI was 9.8% in patients weighing ≥ 120 kg (n = 102) com-
pared to 5.0% in those weighing < 120 kg (n = 202) (p = 0.17).
Three patients (2 obese and 1 non-obese) developed a SSI dur-
ing their admissions and 17 (11 obese and 6 non-obese)
Total number of paents screened
(n=380)
Excluded Paents (n=228)
No prophylacc anbioc given (n=44)
Lack of follow-updata(n=43)
Unplanned non-infecve post-op ICU admissions (n=41)
Mulple procedures/re-operave cases in one
admission/Required blood transfusion (n=24)
Immunosuppressive medicaon (n=21)
Missing data (n=12)
Anbioc on admission for acve infecon (n=9)
Age < 18 years (n=3)






Drug/Dose other than cefazolin 2g (n=20)
o Combinaon anbiocs (n=13)
o Clindamycin 0.6g/1.2g (n=2)
o Vancomycin 1g/1.5g (n=2)
o Ceriaxone 1g (n=1)
o Cefazolin 3g(n=1)
o Gentamicin 240mg (n=1)
Obese Paents (n=152)
Median weight = 133.5kg
Weight < 120kg (n=50)
Weight ≥ 120kg (n=102)
Non-Obese Control Paents (n=152)
Median weight = 72.5kg
Total Included Paents (n=304)
Fig. 1 Flowchart of patient inclusion
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developed SSI post-discharge. Four of the SSIs were classified
as deep (2 obese and 2 non-obese) and 16 as superficial (11
obese and 5 non-obese).
Patients who developed a SSI had a significantly higher ASA
score, longer duration of surgery and longer hospital LOS com-
pared to patients who did not develop a SSI (Table 2). In the
multivariate analysis, however, no variable showed a significant
independent association with SSI (Table 3).
Discussion
The dose of prophylactic antibiotic is an important factor in
SSI prevention, and pharmacokinetic studies provide baseline
information about dose and timing. However, pharmacokinet-
ic findings may not always be translated into clinical out-
comes [23]. Our findings showed no statistically significant
difference in SSI prevalence between obese and non-obese
patients, or those who weighed above and below 120 kg,
who received a 2-g prophylactic cefazolin dose preoperative-
ly. However, there were approximately twofold increases in
SSI prevalence in obese compared to non-obese patients and
in those who weighed ≥ 120 kg compared to those who
weighed < 120 kg. The lack of statistically significant differ-
ences could be due to our relatively small sample size.
To date, no outcome study has shown the superiority of
using a dose of prophylactic cefazolin exceeding 2- g in obese
surgical patients. A retrospective outcome study was
Table 1 Comparison of non-
obese and obese patients Variable Non-obese (n = 152) Obese (n = 152) p value
Gender
Female, n (%) 110 (72.4) 113 (74.3) 0.80
Male, n (%) 42 (27.6) 39 (25.7)
Age (years), median (IQR) 49.0 (30.0–61.0) 46.0 (31.2–54.0) 0.17
Weight (kg), median (IQR) 72.5 (65.0–82.0) 133.5 (115.0–148.0) < 0.001
BMI (kg/m2), median (IQR) 26.7 (24.2–28.6) 47.0 (41.1–52.1) < 0.001
Current smoker, n (%) 43 (28.3) 37 (24.3) 0.52
Diabetes, n (%) 20 (13.2) 54 (35.5) < 0.001
ASA score
1, n (%) 48 (31.6) 2 (1.3) < 0.001
2, n (%) 78 (51.3) 56 (36.8)
3, n (%) 26 (17.1) 94 (61.8)
Length of stay (days), median (IQR) 2.0 (0.0–3.0) 1.0 (1.0–4.0) 0.14
Duration of surgery (min), median (IQR) 60.0 (45.2–89.5) 55.5 (45.0–90.0) 0.95
Implants, n (%) 78 (51.3) 77 (50.7) 1.000
Surgical specialty
General, n (%) 98 (64.5) 98 (64.5) 1.000
Gynaecological, n (%) 41 (27.0) 41 (27.0)
Orthopaedic, n (%) 13 (8.6) 13 (8.6)
Wound class
Clean, n (%) 89 (58.6) 94 (61.8) 0.91
Clean-contaminated, n (%) 61 (40.1) 56 (36.8)
Contaminated, n (%) 1 (0.7) 1 (0.7)
Dirty, n (%) 1 (0.7) 1 (0.7)
Antibiotic prophylaxis recommended (as per TG [7])
Yes, n (%) 149 (98.0) 150 (98.7) 0.65
Post-op antibiotic use
None, n (%) 135 (88.8) 126 (82.9) 0.34
IV, n (%) 14 (9.2) 20 (13.2)
Oral, n (%) 3 (2.0) 6 (3.9)
Post-op antibiotic duration (h)
IV, median (IQR) 20.0 (16.0–24.0) 24.0 (18.0–24.0) 0.36
Oral, median (IQR) 120.0 (48.0–160.0) 180.0 (120.0–240.0) 0.55
Statistically significant values (p<0.05) under the column of p values are shown in italics to highlight such
significance
162 OBES SURG (2019) 29:159–165
Table 2 Relationship of SSI with
patient and clinical characteristics Variables Prevalence of SSI (categorical variable)
or median and IQR (numerical variable)
p value
Gender 1.00
Female, n (%) 15 (6.7)
Male, n (%) 5 (6.2)
Age (years), median (IQR) SSI: 48.5 (28.7–54.0)
No SSI: 47.0 (31.0–57.0)
0.86
Weight (kg), median (IQR) SSI: 118.0 (74.5–139.2)
No SSI: 94.5 (72.2–131.7)
0.18
BMI (kg/m2), median (IQR) SSI: 40.7 (28.3–51.8)
No SSI: 29.8 (26.5–46.9)
0.21
BMI category 0.25
Obese, n (%) 13 (8.6)
Non-obese, n (%) 7 (4.6)
Weight category 0.17
Weight < 120 kg, n (%) 10 (5.0)
Weight ≥ 120 kg, n (%) 10 (9.8)
Current smoker 0.90
Yes, n (%) 6 (7.5)
No, n (%) 14 (6.3)
Diabetes 0.06
Yes, n (%) 9 (12.0)
No, n (%) 11 (4.8)
ASA score 0.02
1, n (%) 1 (2.0)
2, n (%) 5 (3.7)
3, n (%) 14 (11.7)
Length of stay (days), median (IQR) SSI: 4.0 (1.2–5.7)
No SSI: 1.0 (1.0–3.0)
0.001
Duration of surgery (min), median (IQR) SSI: 80.0 (56.2–101.2)
No SSI: 56.5 (45.0–89.5)
0.02
Implants 0.43
Yes, n (%) 8 (5.2)
No, n (%) 12 (8.0)
Surgical specialty 0.94
General, n (%) 13 (6.6)
Gynaecological, n (%) 6 (7.3)
Orthopaedic, n (%) 1 (3.8)
Wound class 0.15
Clean, n (%) 10 (5.5)
Clean-contaminated, n (%) 9 (7.7)
Contaminated, n (%) 0 (0.0)
Dirty, n (%) 1 (50.0)
Post-op antibiotic use (other than for treating SSI) 0.067
No, n (%) 14 (5.4)
IV, n (%) 5 (14.7)
Oral, n (%) 1 (11.1)
Post-op antibiotic duration (h)
Oral, median (IQR) SSI: 120.0 (84.0–240.0)
No SSI: 120.0 (66.0–240.0)
0.90
IV, median (IQR) SSI: 16.0 (16.0–48.0)
No SSI: 24.0 (16.0–24.0)
0.64
Statistically significant values (p<0.05) under the column of p values are shown in italics to highlight such
significance
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conducted of obese (mean BMI = 35 kg/m2; n = 99) and non-
obese (mean BMI = 27 kg/m2; n = 96) patients across various
surgical specialties, who received a 2-g cefazolin prophylactic
dose [24]. No significant difference in 30-day SSI prevalence
was noted between the obese and non-obese groups (7.0% vs
5.2%, p = 0.56) [24]. Likewise, a recent retrospective study of
2- g (mean BMI = 36 kg/m2; n = 152) or 3- g (mean BMI =
40 kg/m2; n = 284) prophylactic cefazolin dosing in obese
patients of various surgical specialties reported a very similar
90-day SSI prevalence in the two dosing groups (7.2% vs
7.4%, p = 0.95) [23]. Our obese cohort had a higher median
BMI (47 kg/m2) compared to patients in the aforementioned
studies (35 kg/m2 and 36 kg/m2) who received a 2-g cefazolin
dose. This is a possible explanation for the larger difference in
SSI prevalence in the obese patients versus control patients in
our study compared to the previous studies [23, 24].
Appropriate prophylactic antibiotic administration is just
one measure of the multifactorial approach used in the pre-
vention of SSI. Therefore, stringent inclusion criteria on pa-
tient selection were applied so that the effect of cefazolin
dosing could be independently estimated. We excluded pa-
tients with factors that can potentially alter the pharmacoki-
netic properties of antibiotics (such as non-infective un-
planned post-operative admissions due to acute illness [25])
or affect the wound healing process (such as peri-operative
blood transfusion and taking immunosuppressive medications
[26]). Furthermore, non-modifiable risk factors, such as older
age, smoking, diabetes, LOS, duration of surgery, pre-existing
implanted medical devices and wound class, were considered
in the statistical analyses.
Patients with diabetes, an ASA score of 3, longer surgery
duration and longer LOS tended to have higher SSI occur-
rence in our study. These are well-established known risk
factors for SSI development [27]. Other SSI risk factors re-
ported in the literature, such as smoking, advanced age and
non-clean surgical wounds [27] in obese patients, did not
show a significant association with SSI.
This study has some limitations. Firstly, it was not a pro-
spective randomised controlled trial. The retrospective study
design meant we had to rely on the notes available in patients’
medical records. For instance, we were not able to record the
exact timing of prophylactic cefazolin dose administration.
However, from the anaesthetic chart reviews, we could ascer-
tain that the doses were always administered in theatre,
anywhere from immediately before induction until shortly af-
ter incision. As mentioned, the sample size of the study was
relatively small. One possible reason for the small number of
patients identified in our case group is that obesity was coded
sporadically in hospital records as a comorbidity (ICD-10 list).
Also, we excluded patients who underwent vascular, urologic,
cardiothoracic and reconstructive surgery due to their limited
numbers, which might compromise the generalisability of
findings to these surgical specialities.
Conclusion
While no statistically significant difference in SSI prevalence
was observed in non-obese and obese patients, or those who
weighed above and below 120 kg, who received a 2-g pro-
phylactic cefazolin dose, trends toward an increase were evi-
dent. There is a clear need for large-scale randomised con-
trolled trials to examine whether a 2-g or 3-g cefazolin dose
is adequate to prevent SSI in obese individuals.
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